Hong Kong Stocks Rebound Following More Than Expected Growth in China's Manufacturing Sector
Hong Kong Stocks Rebound Following More Than Expected Growth in China's Manufacturing Sector
Hong Kong stocks rebounded to start the week in green after staying in red for multiple consecutive sessions as a Caixin report showed more than expected growth in China's manufacturing sector last month despite the contracting official data.
隨着財新報告顯示，儘管官方數據出現收縮，但上個月中國製造業板塊增長超預期，香港股市經過多個連續交易日的市場見紅後，在本週初反彈上漲。
The Hang Seng Index rose by 1.79%, or 323.43 points, to close Monday's session at 18,403.04. The Hang Seng China Enterprises Index rose by 2.18%, or 139.41 points, to close Monday's session at 6,531.99.
恒生指數上漲1.79%或323.43點，報18,403.04，在週一收盤。恒生中國企業指數上漲2.18%或139.41點，報6,531.99，在週一收盤。
Hong Kong's total retail sales slid 14.7% year over year to HK$29.6 billion in April, according to provisional data from the city's Census and Statistics Department released Friday with the rate of decline in April being faster compared with the 7% fall in March.
據香港人口普查及統計處週五發佈的初步數據顯示，香港總零售額在四月同比下降14.7%，達到296億港元。而四月份的下降速度比三月份的7%更快。
In corporate news, UBoT Holding Group (HKG:8529) made a stellar trading debut in Hong Kong Monday morning, opening at HK$0.660 per share, well above its IPO price of HK$0.500. The back-end semiconductor transport media manufacturer's shares closed at HK$0.53, or 6% higher, on Monday.
UBoT控股集團（HKG:8529）週一上午在香港交易所上市，每股開盤價格爲0.66港元，遠高於發行價0.5港元。該後端半導體傳輸媒體制造商的股票週一收盤價爲0.53港元，比上漲6%。
Jacobio Pharmaceuticals (HKG:1167) presented the safety and efficiency data of Glecirasib, or JAB-21822, combined with JAB-3312 for frontline non-small cell lung cancer patients with a KRAS G12C mutation during the 2024 American Society of Clinical Oncology meeting. The company shares rose nearly 12% on Monday's close.
Jacobio Pharmaceuticals（HKG:1167）在2024年美國臨床腫瘤學會會議期間，介紹了與JAB-3312聯合應用的Glecirasib或JAB-21822治療前線非小細胞肺癌患者KRAS G12C基因突變的安全和效能數據。該公司股票週一收盤價上漲近12％。
GenScript Biotech (HKG:1548) received information that two members of the US Congress had sent a letter on May 30, to the Federal Bureau of Investigation and the Office of the Director of National Intelligence to seek information about the company. The company's shares fell by nearly 18% on Monday's close.
GenScript Biotech（HKG:1548）獲悉美國兩名國會議員於5月30日致函聯邦調查局和國家情報主管辦公室，以尋求關於該公司的信息。該公司股票週一收盤價下跌近18％。
譯文內容由第三人軟體翻譯。